Physician profile
Keith A Blakely
NPI 1386799237
$2,236.32
in general payments reported to CMS, 2019-2025
28 companies · $550 in 2025
The $550 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $101 · 2021: $14.17 · 2022: $368 · 2023: $493 · 2024: $356 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,398.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $516.70 | 2022-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $255.09 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $204.33 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $196.72 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $196.56 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $139.26 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.73 | 2022-2025 | Jardiance |
| Exact Sciences Corporation | $73.89 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $61.50 | 2022-2023 | Dificid |
| Novartis Pharmaceuticals Corporation | $57.61 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.97 | 2023-2024 | |
| Amarin Pharma, INC. | $34.66 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $31.06 | 2019 | |
| Sanofi-Aventis U.S. LLC | $30.11 | 2019 | |
| Valeritas, INC. | $28.63 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $28.52 | 2019-2020 | |
| Amgen INC. | $27.47 | 2022-2025 | Repatha, Otezla |
| Astellas Pharma US INC | $27.04 | 2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.97 | 2019 | |
| Almatica Pharma LLC | $26.95 | 2025 | Loreev Xr |
| Abbott Laboratories | $24.94 | 2024 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $22.61 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $22.40 | 2023 | Eliquis |
| Dynavax Technologies Corporation | $21.65 | 2023 | Heplisav-B |
| Biohaven Pharmaceutical Holding Company LTD. | $21.10 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.34 | 2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $15.94 | 2025 | Voquezna |
| Allergan, INC. | $13.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Blakely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.